A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line

AAPS Journal

Volumn 7, Issue 1, 2005, Pages

  Trubetskoy, Olga ^a,b   Marks, Bryan ^a   Zielinski, Thomas ^a   Yueh, Mei Fei ^c   Raucy, Judy ^c,d  

^a INVITROGEN CORPORATION   (United States)

^b Quintessence Biosciences   (United States)

^c Puracyp Inc   (United States)

^d California Toxicol Res Institute   (United States)

Author keywords

CYP3A4; DPX 2 cell line; Drug drug interactions; Induction; Inhibition

Indexed keywords

CLOTRIMAZOLE; COMPACTIN; CYTOCHROME P450 3A4; DEXAMETHASONE; KETOCONAZOLE; LUCIFERASE; MESSENGER RNA; MIFEPRISTONE; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PHENYTOIN; PREGNANE X RECEPTOR; RIFAMPICIN; TROGLITAZONE; TROLEANDOMYCIN; VERAPAMIL;

ARTICLE; CELL ASSAY; CELL CULTURE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMANS; CLOTRIMAZOLE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; DIMETHYL SULFOXIDE; ENHANCER ELEMENTS (GENETICS); ENZYME INDUCTION; GENES, REPORTER; GENES, SYNTHETIC; HUMANS; KETOCONAZOLE; LIVER NEOPLASMS; LOVASTATIN; LUCIFERASES; MIFEPRISTONE; NEOPLASM PROTEINS; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PHENYTOIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RECOMBINANT FUSION PROTEINS; RIFAMPIN; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TROLEANDOMYCIN;

EID: 27644553953     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070102     Document Type: Article

References (36)

1. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett. 2003;140-141:133-143.
2. Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci. 2004;93:239-255.
3. Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions. Eur J Clin Pharmacol. 1999;55:341-347.
4. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol. 1998;55:113-122.
5. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology. 2000;153:1-10.
6. Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction. Curr Opin Drug Discov Devel. 2003;6:50-56.
7. Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:608-612.
8. Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 2000;97:7500-7502.
9. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23:687-702.
10. Bertilsson G, Heidrich J, Svensson Y, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA. 1998;95:12208-12213.
11. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102:1016-1023.
12. Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos. 2004;33:38-48.
13. Raucy JL, Warfe L, Yueh M-F, Allen SW. A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system. J Pharmacol Exp Ther. 2002;303:412-423.
14. Marks BD, Smith RW, Braun HA, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid® P450 substrate. Assay Drug Dev Technol. 2002; 1:73-81.
15. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet. 1992;22:47-65.
16. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev. 2001;27:221-233.
17. Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest. 2003;21:887-896.
18. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628-3634.
19. Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol. 1999;18:95-105.
20. Zlokarnik CY, Volak LP, Andrew MM, Tran C, Cleveland T, Makings LR. Novel fluorescent probes detect different types of CYP450-drug interactions in high throughput mode. Gordon Research Conference on Drug Metabolism; July 9-14,2000; Plymouth, NH.
21. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am. 2000;9:43-76.
22. Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 2001;29:1644-1651.
23. Shen L, Fitzloff JF, Cook CS. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab Dispos. 2004;32:186-196. doi:10.1124/DMD.32.2.186
24. Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development Med Res Rev. 2001;21:397-411.
25. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol. 2000;40:133-157.
26. Michalets EL. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy. 1998;18:84-112.
27. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
28. Parkinson A, Madan A, Forster J, et al. Enzyme induction: assessing the potential for drug interactions. In: Hori W, ed. Drug-Drug Interactions: Analyzing in vitro-in vivo correlations. Westborough, Massachusetts: International Business Communications, Inc;1997. 1-33.
29. Caldwell GW. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physiochemical, in vitro and in vivo screens. Curr Opin Drug Discov Devel. 2000;3:30-41.
30. Fuhr U, Weiss M, Kroemer HK, et al. Systematic screening for pharmacokinetic interactions during drug development. J Clin Pharmacol Therap. 1996;34:139-151.
31. Rodrigues AD. Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochem Pharmacol. 1994;48:2147-2156.
32. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther. 2002;302:475-482.
33. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 2003;31:533-539.
34. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Disp. 2002;30:795-804.
35. Plant NJ, Ogg MS, Crowder M, Gibson GG. Control and statistical analysis of in vitro reporter gene assays. Anal Biochem. 2000;278:170-174.
36. Spink BC, Hussain MM, Katz BH, Eisele L, Spink DC. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem Pharmacol. 2003;66:2313-2321.